Podcast Center
Video Center
Webcasts
Resource Center
Events
December 04, 2014 at 07:25 AM
(Bloomberg — Sanofi’s head of diabetes medicine sales has left the company, weeks after the drugmaker fired its CEO and said revenue from its best-selling insulin will be flat next year, according to people familiar with the matter.
Bob Rossilli, who worked at the Paris-based company’s offices in Bridgewater, New Jersey, left his job the week of Nov. 17, said the people, who asked not to be identified discussing private company matters.
Jack Cox, a spokesman for Sanofi, confirmed that the executive left and declined to comment on reasons for the departure. Rossilli couldn’t immediately be reached for comment. Diabetes sales are now overseen by Scott Oehrlein, vice president and head of general medicines sales, Cox said.
Sanofi surprised investors on Oct. 28 with a tepid forecast for Lantus insulin, and ended Chief Executive Officer Chris Viehbacher six-year tenure the next day. Rossilli was hired under Viehbacher and both are former GlaxoSmithKline Plc managers.
Before he was fired, Viehbacher told investors that Sanofi cut Lantus prices last quarter to get on U.S. drug benefit managers’ reimbursement lists in the face of competition from Novo Nordisk A/S, the world’s biggest insulin maker. Since 2007, U.S. prices for one form of Lantus have increased 160 percent. The prices for another form have increased 97 percent.
